Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST.
Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company
Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on
New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track Montreal, Canada, October 3, 2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV
Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated
Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated
Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was
Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Cambridge, MA, June 15, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock
Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, June 13, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offering of 11,750,000 shares of common stock. The gross proceeds, before commissions and expenses, of
Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in
Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs’ Twenty-Sixth Annual Global Healthcare Conference Cambridge, MA, June 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Goldman Sachs' 26th Annual Global Healthcare
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, June 7, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the pricing of its public offering of 11,750,000 shares of its common stock at a price of $13.00 per share.
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, May 31, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 9,500,000 shares of its newly issued common stock in an underwritten public offering.
Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders Cambridge, MA, May 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will webcast its 2005 Annual Meeting of Shareholders on Wednesday, May 11, 2005. Joshua Boger, Ph.D., Vertex's Chairman and Chief Executive
New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir Quebec City, April 29, 2005 --Today new study results announced by GlaxoSmithKline showed the pharmacokinetics (PK) of the HIV protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed in combination with
New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium Quebec City, April 29, 2005 --Today GlaxoSmithKline (GSK) presented new pharmacokinetic (PK) data on taking the HIV protease inhibitor LEXIVA(R) (fosamprenavir calcium, FPV) Tablets with the proton pump inhibitor (PPI), Nexium(R)
Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, April 27, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at Deutsche Bank's 30th Annual Health Care Conference on May 2, 2005 and at Morgan Stanley's
Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update Cambridge, MA, April 26, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended March 31, 2005.
Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast Cambridge, MA, April 4, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its first quarter 2005 financial results on Tuesday, April 26, 2005 after the financial
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference Cambridge, MA, March 11, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at SG Cowen's 25th Annual Health Care Conference in Boston.
Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals Cambridge, MA, February 23, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the United States District Court for the District of Massachusetts has granted its motion to dismiss a
Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, February 18, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the BIO CEO and Investor Conference on February 23, 2005 and at the SunTrust Robinson
Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer Cambridge, MA, and Germantown, MD, February 15, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Avalon Pharmaceuticals Incorporated today announced that
Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance Cambridge, MA, February 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ending December 31, 2004.
Vertex Pharmaceuticals Announces Two Senior Management Changes Cambridge, MA, February 8, 2005 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that Dr. Vicki Sato will retire as President of the Company effective during the second quarter of 2005. Dr.
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference Cambridge, MA, February 3, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Merrill Lynch's
Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast Cambridge, MA, February 2, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its fourth quarter and full year 2004 financial results on Wednesday,
Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005
Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at JPMorgan's 23rd Annual Healthcare Conference in San
Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART Montego Bay, Jamaica, December 15, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD)
